Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports safety, tolerability, and pharmacokinetic/pharmacodynamic data for crinecerfont (NBI-74788) in pediatric participants…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• NBI-74788 (Crinecerfont) (Crinecerfont)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: CAH - Congenital Adrenal Hyperplasia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-18